EXAGEN INC. Research and Development Expense
EXAGEN INC. (XGN) reported Research and Development Expense of $1.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- EXAGEN INC. research and development expense for the quarter ending 2026-06-30 was $1.43M, a 3.84% decline year-over-year.
- EXAGEN INC. research and development expense for the quarter ending 2026-03-31 was $1.55M, a 20.95% increase year-over-year.
- EXAGEN INC. research and development expense for the quarter ending 2025-12-31 was $1.76M, a 6.10% increase year-over-year.
- EXAGEN INC. research and development expense for the quarter ending 2025-09-30 was $1.73M, a 16.81% increase year-over-year.
- EXAGEN INC. research and development expense for fiscal 2025 was $6.25M, a 16.35% increase from fiscal 2024.
- EXAGEN INC. research and development expense for fiscal 2024 was $5.38M, a 10.48% increase from fiscal 2023.
- EXAGEN INC. research and development expense for fiscal 2023 was $4.87M, a 50.74% decline from fiscal 2022.
- EXAGEN INC. research and development expense for fiscal 2022 was $9.88M, a 36.47% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.43M 10-Q · filed 2026-08-04 | $2.98M 10-Q · filed 2026-08-04 | $4.74M derived: sum of 3 quarters · filed 2026-08-04 | $6.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.55M 10-Q · filed 2026-05-11 | $3.31M derived: sum of 2 quarters · filed 2026-05-11 | $5.04M derived: sum of 3 quarters · filed 2026-05-11 | $6.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.49M derived: sum of 2 quarters · filed 2026-03-10 | $4.97M derived: sum of 3 quarters · filed 2026-08-04 | $6.25M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.73M 10-Q · filed 2025-11-04 | $3.21M derived: sum of 2 quarters · filed 2026-08-04 | $4.50M 10-Q · filed 2025-11-04 | $6.15M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.48M 10-Q · filed 2026-08-04 | $2.77M 10-Q · filed 2026-08-04 | $4.42M derived: sum of 3 quarters · filed 2026-08-04 | $5.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.28M 10-Q · filed 2026-05-11 | $2.94M derived: sum of 2 quarters · filed 2026-05-11 | $4.42M derived: sum of 3 quarters · filed 2026-05-11 | $5.60M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.14M derived: sum of 2 quarters · filed 2026-03-10 | $4.32M derived: sum of 3 quarters · filed 2026-03-10 | $5.38M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.48M 10-Q · filed 2025-11-04 | $2.66M derived: sum of 2 quarters · filed 2025-11-04 | $3.72M 10-Q · filed 2025-11-04 | $4.79M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.18M 10-Q · filed 2025-07-29 | $2.24M 10-Q · filed 2025-07-29 | $3.31M derived: sum of 3 quarters · filed 2025-07-29 | $4.71M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $1.06M 10-Q · filed 2025-05-05 | $2.13M derived: sum of 2 quarters · filed 2025-05-05 | $3.54M derived: sum of 3 quarters · filed 2025-05-05 | $4.80M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.48M derived: sum of 2 quarters · filed 2025-03-11 | $3.74M derived: sum of 3 quarters · filed 2025-03-11 | $4.87M 10-K · filed 2025-03-11 |
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-12 | $2.66M derived: sum of 2 quarters · filed 2024-11-12 | $3.79M 10-Q · filed 2024-11-12 | $6.49M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.26M 10-Q · filed 2024-08-05 | $2.39M 10-Q · filed 2024-08-05 | $5.09M derived: sum of 3 quarters · filed 2024-08-05 | $7.47M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $1.13M 10-Q · filed 2024-05-13 | $3.83M derived: sum of 2 quarters · filed 2024-05-13 | $6.21M derived: sum of 3 quarters · filed 2024-05-13 | $8.90M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $5.08M derived: sum of 2 quarters · filed 2024-03-18 | $7.77M derived: sum of 3 quarters · filed 2024-03-18 | $9.88M 10-K · filed 2024-03-18 |
| 2022-09-30 | $2.38M 10-Q · filed 2023-11-13 | $5.07M derived: sum of 2 quarters · filed 2023-11-13 | $7.17M 10-Q · filed 2023-11-13 | $9.38M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.69M 10-Q · filed 2023-08-07 | $4.79M 10-Q · filed 2023-08-07 | $7.00M derived: sum of 3 quarters · filed 2023-08-07 | $8.73M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $2.10M 10-Q · filed 2023-05-15 | $4.31M derived: sum of 2 quarters · filed 2023-05-15 | $6.05M derived: sum of 3 quarters · filed 2023-05-15 | $7.94M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $3.94M derived: sum of 2 quarters · filed 2023-03-20 | $5.83M derived: sum of 3 quarters · filed 2023-03-20 | $7.24M 10-K · filed 2023-03-20 |
| 2021-09-30 | $1.74M 10-Q · filed 2022-11-21 | $3.63M derived: sum of 2 quarters · filed 2022-11-21 | $5.04M 10-Q · filed 2022-11-21 | $6.20M derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-06-30 | $1.89M 10-Q/A · filed 2022-11-21 | $3.29M 10-Q/A · filed 2022-11-21 | $4.46M derived: sum of 3 quarters · filed 2022-11-21 | $5.48M derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-11 | $2.57M derived: sum of 2 quarters · filed 2022-05-11 | $3.59M derived: sum of 3 quarters · filed 2022-05-11 | $4.34M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.18M derived: sum of 2 quarters · filed 2022-03-22 | $2.93M derived: sum of 3 quarters · filed 2022-03-22 | $3.57M 10-K · filed 2022-03-22 |
| 2020-09-30 | $1.02M 10-Q · filed 2021-11-10 | $1.77M derived: sum of 2 quarters · filed 2021-11-10 | $2.40M 10-Q · filed 2021-11-10 | $2.97M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $751.00K 10-Q · filed 2021-08-09 | $1.39M 10-Q · filed 2021-08-09 | $1.95M derived: sum of 3 quarters · filed 2021-08-09 | $2.46M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $634.00K 10-Q · filed 2021-05-11 | $1.20M derived: sum of 2 quarters · filed 2021-05-11 | $1.71M derived: sum of 3 quarters · filed 2021-05-11 | $2.30M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.07M derived: sum of 2 quarters · filed 2021-03-16 | $1.66M derived: sum of 3 quarters · filed 2021-03-16 | $2.18M 10-K · filed 2021-03-16 |
| 2019-09-30 | $507.00K 10-Q · filed 2020-11-10 | $1.10M derived: sum of 2 quarters · filed 2020-11-10 | $1.61M 10-Q · filed 2020-11-10 | $2.14M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $590.00K 10-Q · filed 2020-07-28 | $1.10M 10-Q · filed 2020-07-28 | $1.64M derived: sum of 3 quarters · filed 2020-07-28 | $2.16M derived: sum of 4 quarters · filed 2020-07-28 |
| 2019-03-31 | $513.00K 10-Q · filed 2020-05-11 | $1.05M derived: sum of 2 quarters · filed 2020-05-11 | $1.57M derived: sum of 3 quarters · filed 2020-05-11 | |
| 2018-12-31 | $533.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $1.06M derived: sum of 2 quarters · filed 2020-03-25 | $2.13M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $525.00K 10-Q · filed 2019-11-12 | $1.59M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |